

# George N Dalekos

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/993460/george-n-dalekos-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187  
papers

6,214  
citations

41  
h-index

74  
g-index

197  
ext. papers

7,968  
ext. citations

5.6  
avg. IF

5.51  
L-index

#	Paper	IF	Citations
187	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 169-76	11.2	1166
186	Peginterferon plus adefovir versus either drug alone for hepatitis delta. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 322-31	59.2	303
185	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 800-6	13.4	227
184	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
183	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , <b>2017</b> , 66, 1444-1453	11.2	180
182	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , <b>2014</b> , 60, 87-97	11.2	159
181	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 363-70	13.4	124
180	Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 636-646	13.4	124
179	Review article: autoimmune hepatitis -- current management and challenges. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 887-913	6.1	109
178	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 436-42	15.5	103
177	Adipokines as mediators of endothelial function and atherosclerosis. <i>Atherosclerosis</i> , <b>2013</b> , 227, 216-21	3.1	95
176	Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. <i>Journal of Autoimmune Diseases</i> , <b>2004</b> , 1, 2		94
175	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1752-1760 <sup>50.5</sup>		93
174	Hepatocyte autotaxin expression promotes liver fibrosis and cancer. <i>Hepatology</i> , <b>2017</b> , 65, 1369-1383	11.2	90
173	Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 60-83	5.6	89
172	Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. <i>Journal of Translational Internal Medicine</i> , <b>2015</b> , 3, 43-50	3	88
171	Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 949-56	13.4	75

170	Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 389-96	13.6	69
169	Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , <b>2010</b> , 30, 430-7	7.9	66
168	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1129-1136	13.4	64
167	A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1035-47	6.1	58
166	An open label trial of anakinra to prevent respiratory failure in COVID-19. <i>ELife</i> , <b>2021</b> , 10,	8.9	57
165	Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. <i>European Journal of Clinical Investigation</i> , <b>2003</b> , 33, 161-8	4.6	56
164	Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2000</b> , 12, 67-74	2.2	56
163	Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome. <i>International Journal of Infectious Diseases</i> , <b>2009</b> , 13, 564-9	10.5	54
162	Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. <i>Liver International</i> , <b>2007</b> , 27, 1226-31	7.9	52
161	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1088-1096	13.4	50
160	Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 807-12	3.3	49
159	Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. <i>Clinical Immunology</i> , <b>2006</b> , 119, 203-12	9	48
158	Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. <i>Journal of Clinical Immunology</i> , <b>2007</b> , 27, 378-87	5.7	47
157	Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. <i>Clinical and Experimental Medicine</i> , <b>2014</b> , 14, 121-31	4.9	46
156	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. <i>Hepatology</i> , <b>2007</b> , 45, 1583; author reply 1583-4	11.2	46
155	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , <b>2019</b> , 105, 102328	15.5	45
154	Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 605-14	0.7	45
153	The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. <i>Journal of Autoimmune Diseases</i> , <b>2007</b> , 4, 3		45

152	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 254-264	0.7	44
151	DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 677-685	1.6	43
150	Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 $\beta$ -lactamase. <i>International Journal of Antimicrobial Agents</i> , <b>2012</b> , 39, 247-50	14.3	42
149	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , <b>2018</b> , 38, 842-850	7.9	41
148	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2342-49.e1-2	6.9	41
147	Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?. <i>Liver International</i> , <b>2012</b> , 32, 544-53	7.9	41
146	Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Autoimmunity</i> , <b>2005</b> , 24, 251-60	15.5	41
145	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
144	Occult hepatitis B virus infection in patients with autoimmune liver diseases. <i>Liver International</i> , <b>2009</b> , 29, 434-42	7.9	39
143	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e690-e697	14.2	38
142	Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 35-42	2.2	36
141	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , <b>2018</b> , 67, 1920-1930	11.2	35
140	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1037-1045	13.4	34
139	Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. <i>Hepatology Research</i> , <b>2019</b> , 49, 96-104	5.1	34
138	Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 102-109	4.1	33
137	IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. <i>Journal of Clinical Immunology</i> , <b>2008</b> , 28, 501-11	5.7	33
136	Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , <b>2007</b> , 380, 118-21	6.2	33
135	Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. <i>Autoimmunity</i> , <b>2013</b> , 46, 471-9	3	32

134	Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. <i>Liver International</i> , <b>2015</b> , 35, 660-72	7.9	31
133	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1066-1074	0.7	31
132	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1127-1136	6.1	29
131	Geoeidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 42, 81-88	3.9	28
130	Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 225-31	5.6	28
129	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2076-2084.e2	6.9	27
128	Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 387-92	3.4	27
127	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 127-135	3.1	26
126	Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 1-23	2.2	25
125	Oxidative stress and antioxidant status in patients with autoimmune liver diseases. <i>Redox Report</i> , <b>2015</b> , 20, 33-41	5.9	24
124	On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , <b>2015</b> , 35, 1540-8	7.9	24
123	Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. <i>IScience</i> , <b>2021</b> , 24, 101947	6.1	23
122	Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 528-536	6.1	21
121	Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. <i>International Journal of Infectious Diseases</i> , <b>2009</b> , 13, e157-60	10.5	21
120	Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2009</b> , 21, 1220	2.2	21
119	Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- $\alpha$ treatment. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 305-12	1.6	20
118	Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 454-5	4	20
117	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 118-126	3.4	20

116	Molecular diagnostic testing for primary biliary cholangitis. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 1001-10	3.8	20
115	Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece. <i>International Journal of Infectious Diseases</i> , <b>2015</b> , 34, 46-50	10.5	19
114	Molecular diagnostics of primary biliary cirrhosis. <i>Expert Opinion on Medical Diagnostics</i> , <b>2008</b> , 2, 621-34		19
113	Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 848-55	13.4	19
112	Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. <i>European Journal of Internal Medicine</i> , <b>2009</b> , 20, 35-43	3.9	18
111	JAK Inhibitors and Oxidative Stress Control. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2814	8.4	18
110	JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2020</b> , 58, 182-193	12.3	18
109	Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. <i>Journal of Autoimmune Diseases</i> , <b>2007</b> , 4, 2		17
108	Low Serum Hepcidin in Patients with Autoimmune Liver Diseases. <i>PLoS ONE</i> , <b>2015</b> , 10, e0135486	3.7	17
107	Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1875-83	3.4	17
106	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23, 560-8	1	17
105	COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 38, 83-88	3.9	16
104	Use of TNF $\alpha$ antagonists in refractory AIH: revealing the unforeseen. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 197-8	13.4	16
103	Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2012</b> , 36, 84-93	2.4	16
102	Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , <b>2010</b> , 411, 411-5	6.2	16
101	Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. <i>Liver International</i> , <b>2007</b> , 27, 280-3	7.9	16
100	Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. <i>Clinica Chimica Acta</i> , <b>2006</b> , 373, 183-4; author reply 185	6.2	16
99	Treatment of chronic hepatitis C with direct-acting antivirals in patients with $\beta$ -thalassaemia major and advanced liver disease. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 130-136	4.5	15

98	Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 147-151	3.1	15
97	Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 577-83	3.4	15
96	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1359-1368	3.4	14
95	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , <b>2013</b> , 13, 127-35	3.1	14
94	Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. <i>JHEP Reports</i> , <b>2020</b> , 2, 100123	10.3	13
93	Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. <i>Journal of Medical Case Reports</i> , <b>2011</b> , 5, 22	1.2	13
92	Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 4721-8	5.6	13
91	NAFLD and autoimmune hepatitis: Do not judge a book by its cover. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 75, 1-9	3.9	12
90	IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. <i>Clinica Chimica Acta</i> , <b>2012</b> , 413, 1683-8	6.2	12
89	Anti-neutrophil antibodies in chronic viral hepatitis. <i>Journal of Hepatology</i> , <b>1994</b> , 20, 561	13.4	11
88	Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 5130-5145	5.6	11
87	Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. <i>Liver International</i> , <b>2020</b> , 40, 368-376	7.9	11
86	Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. <i>Experimental Biology and Medicine</i> , <b>2006</b> , 231, 1653-63	3.7	10
85	Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1994</b> , 6, 547-552	2.2	10
84	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 684-692.e6	6.9	10
83	An immunocompetent patient presenting with severe septic arthritis due to <i>Ralstonia pickettii</i> identified by molecular-based assays: a case report. <i>Cases Journal</i> , <b>2009</b> , 2, 8125		9
82	Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. <i>Occupational Medicine</i> , <b>2008</b> , 58, 305-7	2.1	9
81	Features and outcome of AIH patients without elevation of IgG. <i>JHEP Reports</i> , <b>2020</b> , 2, 100094	10.3	9

80	Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2019</b> , 67, 197-211	4	8
79	Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2015</b> , 24, 721-4 <sup>2.8</sup>		8
78	Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message?. <i>Liver International</i> , <b>2008</b> , 28, 426-8	7.9	8
77	Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 2839-53	5.6	8
76	Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2017</b> , 9, e2017003	3.2	8
75	Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 147-51	3.1	8
74	Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 699-708	3.4	7
73	Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. <i>European Journal of Internal Medicine</i> , <b>2011</b> , 22, e155-7	3.9	7
72	Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , <b>2008</b> , 6, 855-9	5.5	7
71	FRI-029-Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e396-e397	13.4	6
70	Bone marrow findings in patients with autoimmune liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, e416-21	4	6
69	How common are connective tissue disorders in patients with autoimmune hepatitis?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 332; author reply 333	5.3	6
68	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
67	Spontaneous bacterial peritonitis: an unusual manifestation of brucellosis in a previous healthy male patient. <i>BMJ Case Reports</i> , <b>2015</b> , 2015,	0.9	6
66	Management of Patients with Liver Cirrhosis and Invasive Bladder Cancer: A Case-series. <i>Journal of Translational Internal Medicine</i> , <b>2019</b> , 7, 29-33	3	6
65	Linking genetic variation with epigenetic profiles in Sjögren's syndrome. <i>Clinical Immunology</i> , <b>2020</b> , 210, 108314	9	6
64	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 312-320	13.4	6
63	Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis. <i>Case Reports in Hepatology</i> , <b>2018</b> , 2018, 9793868	0.9	6



62	Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late?. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 43, e48-e49	3.9	5
61	Point-prevalence survey of healthcare facility-onset healthcare-associated <i>Clostridium difficile</i> infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182799	3.7	5
60	Aiming towards hepatitis C virus elimination in Greece. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 321-329	2.2	5
59	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , <b>2014</b> , 34, 1207-15	7.9	5
58	Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. <i>Liver International</i> , <b>2011</b> , 31, 277-9	7.9	5
57	Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. <i>Internal Medicine</i> , <b>2012</b> , 51, 1077-80	1.1	5
56	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	5
55	Decreased serum DNase1-activity in patients with autoimmune liver diseases. <i>Autoimmunity</i> , <b>2017</b> , 50, 125-132	3	4
54	Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?. <i>Liver Transplantation</i> , <b>2019</b> , 25, 1588-1589	4.5	4
53	Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 123-126	2.2	4
52	Lack of association between appendectomy and primary biliary cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2006</b> , 41, 573-6	2.4	4
51	Variants of Primary Biliary Cholangitis: An Updated Mini-Review6, 21-28		4
50	Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and Immunglobulin infusions. <i>World Journal of Clinical Cases</i> , <b>2019</b> , 7, 3394-3406	1.6	4
49	Efficacy of Interferon A-2b monotherapy in Ethalassemics with chronic hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2015</b> , 24, 189-96	1.4	4
48	SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. <i>Hepatology Communications</i> , <b>2021</b> ,	6	4
47	Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. <i>Liver International</i> , <b>2021</b> , 41, 1592-1599	7.9	4
46	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 88, 52-62	3.9	4
45	Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2019</b> , 43, e25-e32	2.4	4

44	Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
43	Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis.. <i>Epigenomes</i> , <b>2019</b> , 3,	2.3	3
42	Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. <i>Gastroenterology Research and Practice</i> , <b>2010</b> , 2010,	2	3
41	Autoimmune hepatitis: of host and pathogen. <i>Hepatology</i> , <b>2008</b> , 47, 2147-8	11.2	3
40	Unexplained choroidal embolisation: remember the antiphospholipid syndrome. <i>Lancet, The</i> , <b>2006</b> , 368, 1936	40	3
39	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients. <i>Journal of Innate Immunity</i> , <b>2021</b> , 1-11	6.9	3
38	Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
37	Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 86-91	3.9	3
36	Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis?. <i>Journal of Translational Internal Medicine</i> , <b>2021</b> , 9, 43-51	3	3
35	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100560	18	3
34	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	3
33	Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. <i>BMJ Case Reports</i> , <b>2019</b> , 12,	0.9	2
32	Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	2
31	Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. <i>BMJ Case Reports</i> , <b>2020</b> , 13,	0.9	2
30	Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts?. <i>European Journal of Case Reports in Internal Medicine</i> , <b>2016</b> , 3, 000396	1.3	2
29	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 73-79	2.2	2
28	Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. <i>Annals of Gastroenterology</i> , <b>2017</b> , 30, 542-549	2.2	2
27	Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	2

26	FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. <i>Annals of Hepatology</i> , <b>2021</b> , 22, 100285	3.1	2
25	Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100321	10.3	2
24	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2021</b> ,	11.2	2
23	MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19. <i>Immunobiology</i> , <b>2021</b> , 226, 152136	3.4	2
22	Which level of immunosuppression is harmful for occult hepatitis B virus infection?: A million dollar answer. <i>Liver International</i> , <b>2009</b> , 29, 1127-1128	7.9	1
21	Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution.. <i>Microorganisms</i> , <b>2022</b> , 10,	4.9	1
20	First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naïve AIH Patients.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 798602	8.4	1
19	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
18	Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis		1
17	The changing epidemiology of hepatitis B in Greece. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 431-437	2.2	1
16	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients		1
15	Rifampicin: not always an innocent drug. <i>BMJ Case Reports</i> , <b>2018</b> , 11,	0.9	1
14	Impact of genetic and environmental factors on autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , <b>2021</b> , 4, 100125	4.1	1
13	A chronic alcoholic man with high fever, neck rigidity and loss of consciousness: remember the Austrian syndrome a commonly unrecognised invasive pneumococcus triad. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	0
12	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , <b>2021</b> , 3, 100290	10.3	0
11	CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. <i>Liver International</i> , <b>2021</b> , 41, 123-127	7.9	0
10	Programmed cell death-1 and interleukin-28B polymorphisms in autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , <b>2021</b> , 4, 100126	4.1	0
9	ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. <i>Liver International</i> , <b>2021</b> ,	7.9	0

8	Reply to "Further considerations in autoimmune hepatitis". <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1458-9	13.4
7	Could the 90s be a second childhood period? The case of Henoch-Schonlein purpura. <i>Age and Ageing</i> , <b>2008</b> , 37, 483	3
6	Severe Pharyngodynia Followed by Migratory Polyarthritits and High Fever in Young Immigrants: Remember That Rheumatic Fever Is Still Relevant in 2020!. <i>Case Reports in Infectious Diseases</i> , <b>2020</b> , 2020, 8854868	0.9
5	521. Similarities and Differences in Transcriptomic Host Response between SARS-CoV-2 and Other Viral Infections. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S326-S327	1
4	PSC-AIH Overlap <b>2020</b> , 359-373	
3	Hepatic brucelloma: a rare complication of a common zoonotic disease. <i>BMJ Case Reports</i> , <b>2020</b> , 13,	0.9
2	p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 52-60	3.4
1	An Immunocompetent HIV-Negative Elderly Patient with Low-Grade Fever, Generalized Lymphadenopathy, Splenomegaly, and Acute Phase Response: Do Not Forget Castleman Disease. <i>Case Reports in Infectious Diseases</i> , <b>2021</b> , 2021, 6614208	0.9